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ABSTRACT
Hepatitis C virus (HCV) infection is known to cause acute and chronic active hepatitis. In addition, HCV also has 
systemic disorder involvement that links to various extra-hepatic complications. We report a case of a patient which 
has been diagnosed to have Hepatitis C Genotype 3A who has been started on antiviral. He achieved end treatment 
response and sustained virologic response. During routine follow up, he experienced acute kidney injury. Renal 
biopsy showed type III membranoproliferative glomerulonephritis. His proteinuria improved greatly with the addi-
tion of angiotensin converting enzyme inhibitor. This case highlights the possibility of appearance of HCV related 
glomerulonephritis in patient who has sustained virological response.
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INTRODUCTION
Hepatitis C virus (HCV) has been categorized as 
the only member of the genus hepacivirus.  The 
association between HCV and kidney disease has been 
increasingly established. Patients with HCV related 
glomerulonephritis (GN) commonly present with 
asymptomatic proteinuria, microscopic hematuria and 
varying degrees of renal insufficiency. In almost all cases, 
the extra-hepatic manifestations are directly related to 
the presence of active HCV infection. We report here a 
case of unusual form of MPGN that occur after the HCV 
infection is in remission.
CASE REPORT
A forty-three-year old gentleman with a history of 
hypertension and dyslipidemia was diagnosed as having 
chronic HCV in 2010. His HCV was of genotype 3A 
with pre-treatment HCV RNA level of 324,000 IU/ML. 
He has completed 24-weeks pegylated interferon alfa-
2a in October 2011. He achieved both end of treatment 
response (ETR) on 3rd of Nov 2011 and achieved 
sustained virologic response (SVR) on 29/5/2012. His 
HCV RNA level done yearly remains undetected.
His usual medications include tablet hydrochlorothiazide 
25mg daily, tablet atenolol 25mg daily for his 
hypertension and tablet Simvastatin 40mg at night for 
his dyslipidemia. He was referred to the nephrology 
department in February 2017 when he was found that 
he found to have an elevated serum creatinine of 147 
µmol/L (61 mL/min per 1.73 m2) during one of the 
regular medical check-ups. His baseline creatinine in 
2012 was noted to be in normal range of 70-90 µmol/L. 
Systemic examinations were unremarkable and his 
blood pressure readings were within normal limit. His 
initial blood investigations in February 2017 are as 
follow: hemoglobin 13 g/dL, total white blood cell 13.4 
x109/L, platelet 373 x109/L, urea 8 mmol/L, sodium 141 
mmol/L, potassium 3.1 mmol/L, creatinine 217 µmol/L, 
serum albumin 25 g/L, corrected calcium 2.3 mmol/L 
and inorganic phosphate 1.29 mmol/L. His antinuclear 
antibody, complements level and thyroid function test 
were normal. Urine analysis shows albumin 4+ and his 
24 hours urinary protein was 12 g.
The patient’s ultrasound scan of the kidneys was normal 
in size and echogenicity with cortical thickness of 2.0 – 
2.4cm. In view of his persistent significant proteinuria in 
nephrotic range, he was planned for renal biopsy. The 
renal histology showed rigid and thickened capillary 
walls (Fig 1). Subepithelial spikes and deposits are 
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Figure 1:  H & E stains : Rigid and thickened capillary 
walls
Figure 2:  PAAG stains.  Subepithelial spikes and 
deposits are diffusely seen with tram track duplication 
of basement membrane suggestive of subendothelial 
deposits
diffusely seen with tram track duplication of basement 
membrane suggestive of subendothelial deposits (Fig 2). 
There is no HCV virus particle identified.
Immunohistochemical staining showed granular 
positivity along the basement membrane for 
Immunoglobulin (IG) M and C4d. IgG, IgA, C3 and C1q 
are negative.  Morphological wise, the description fits 
for a Type III MPGN. He was started on perindopril 
8mg and his renal function has been making gradual 
improvement with the latest serum creatinine of 154 
µmol/L, albumin 39g/L and 2+ dipstick albuminuria in 
August 2018.
manifestations in patients infected with HCV includes 
microscopic hematuria, proteinuria, acute nephritis 
and nephrotic syndrome. However most of the renal 
disease is asymptomatic as per our case. Apart from 
renal involvement, other established extra-hepatic 
manifestations include HCV-related autoimmune 
or lymphoproliferative disorders (benign mixed 
cryoglobulinemia to frank lymphomas), seronegative 
arthritis, cardiovascular disease, glucose metabolism 
disease and central nervous system disease. Our patient 
initial impaired renal function could be due to acute 
flare of MPGN.
Membranoproliferative glomerulonephritis (MPGN) is 
an extremely rare form of glomerulonephritis where it 
is characterized by the presence of matrix expansion, 
increased cellularity at the glomerular tufts with 
thickening of the capillary walls.  The cause of MPGN 
may be idiopathic or secondary. Secondary causes are 
usually due to infection by viral, bacterial, and parasite. 
Traditionally, the classification of MPGN is dependent 
on the electron microscopic changes in the glomerular 
basement membrane (GBM). This can be type I 
(subendothelial deposits), type II (intramembraneous 
dense deposits) or type III (3). In type III MPGN, immune 
deposits are deposit in the subendothelial and mesangial 
regions. In addition, subepithelial deposition will occur. 
This classification can result in overlap between types 
I and III where both types it thought to be immune 
complex-mediated mediated.
MPGN arising from chronic antigenemia and/
or circulating immune complexes can be seen in 
inflammatory conditions such as chronic infections, 
autoimmune diseases, and monoclonal gammopathies. 
MPGN resulting from HCV infection typically shows 
granular deposition of immunoglobulin M (IgM), C3, and 
both kappa and lambda light chains. Immunoglobulin G 
may or may not be present, and C1q is typically negative. 
This pattern may also be seen with MPGN induced 
by other viral infections (4). In MPGN, complement 
activation typically occurs and the C3 and C4 level is 
low. However, MPGN can have normal complement 
level as it can be caused by other postulated mechanism 
such as endothelial injury.
The pathogenesis of HCV related glomerulonephritis 
still remains unclear. Many consider that the deposition 
of immune complexes particles containing HCV in 
kidney disease is related to the on-going HCV infection. 
Ideally HCV antigens or HCV should be present in 
diseased glomeruli if HCV is the culprit causing the 
immune deposition. Yet, HCV antigens or RNA in the 
glomerular lesions has rarely been isolated or identified. 
This is similar to our case where the HCV particles are 
not identified in our renal biopsy. The possible reasons 
are masking of the antigen by various antibodies or the 
presence of small amount of HCV antigen or RNA which 
is below the detection limit (5).
DISCUSSION
HCV-positive and chronic kidney disease (CKD) has 
always been known to be associated with each other. 
A meta-analysis shows patients with HCV-positive had 
a 23% greater risk of association with chronic kidney 
disease compared to uninfected individuals (1). A cohort 
study of a group of CKD patients also shows increase 
association between HCV infection in developing 
End Stage Renal Disease (ESRD) (2).  Common renal 
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Another interesting fact is that the appearance of MPGN 
in a HCV -affected patient that has been under SVR for 
more than 5 years. His complements level were also 
normal. This is to contrast with most of the confirmed 
cases of HCV related glomerulonephritis where there 
were clear evidence of active HCV Infections as 
demonstrated by the raised HCV RNA titires in the 
serum. He has no other known trigger for the appearance 
of MPGN.
There are 3 mainstay treatments that has been proposed 
to prevent the synthesis of immune-complexes and 
further damage of HCV on kidneys, namely HCV 
antiviral therapy, B-cell depletion therapy like 
rituximab and nonspecific immunosuppressive therapy 
like cyclophosphamide, mycophenolate mofetil and 
corticosteroids reducing inflammatory cells. In case in 
the presence of significant proteinuria and hypertension, 
renoprotection with antihypertensive and antiproteinuric 
agents such as renin-angiotensin system inhibitors and 
diuretics should be prescribed as needed. The efficacy 
of various forms of treatment for MPGN remains 
controversial; however, long-term steroid treatment 
seems to be effective only in children with nephrotic-
range proteinuria.
This case has alerted us that despite Hepatitis C 
patient has sustained viral response, they should be 
continuously monitor for the appearance of extra-
hepatic complications.
CONCLUSION
Our case highlights the need to have a high index of 
suspicion of HCV related glomerulonephritis in patient 
with HCV regardless whether they have achieved 
sustained virological response or not, especially those 
who had unexplained proteinuria, hematuria or derange 
renal function. Early recognition and high index of 
suspicion is needed so that renal biopsy and tailored 
treatment can be administered in a timely manner.
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